Lipid re-screening: what is the best measure and interval?
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Objectives: To estimate the long-term true change variation (‘signal’) and short-term within-person variation (‘noise’) of the different lipid measures and evaluate the best measure and the optimal interval for lipid re-screening. Design: Retrospective cohort study from 2005 to 2008. Setting: A medical health check-up programme at a centre for preventive medicine in a teaching hospital in Tokyo, Japan. Participants: 15 810 apparently healthy Japanese adults not taking cholesterol-lowering drugs at baseline, with a mean body mass index of 22.5 kg/m 2 (SD 3.2). Main outcome measures: Annual measurement of the serum total cholesterol (TC), low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and calculation of the ratio of TC/HDL and LDL/HDL. Measurement of the ratio of long-term true change variation (‘signal’) to the short-term within-person variation (‘noise’) for each measure. Results: At baseline, participants (53% male) with a mean age of 49 years (range 21–92) and a mean TC level of 5.3 mmol/l (SD 0.9 mmol/l) had annual check-ups over 4 years. Short-term within-person variations of TC, LDL, HDL, TC/HDL, and LDL/HDL were 0.12 (coefficient of variation (CV) 6.4%), 0.08 (CV 9.4%), 0.02 (CV 8.0%) mmol 2/l 2, 0.08 (CV 7.9%) and 0.05 (CV 10.6%), respectively. The ratio of signal-to-noise at 3 years was largest for TC/HDL (1.6), followed by LDL/HDL (1.5), LDL (0.99), TC (0.8) and HDL (0.7), suggesting that cholesterol ratios are more sensitive re-screening measures. Conclusion: The signal-to-noise ratios of standard single lipid measures (TC, LDL and HDL) are weak over 3 years and decisions based on these measures are potentially misleading. The ratios, TC/HDL and LDL/HDL, seem to be better measures for monitoring assessments. The lipid re-screening interval should be >3 years for those not taking cholesterol-lowering drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ridker, P. M., Rifai, N., Cook, N. R., Bradwin, G., & Buring, J. E. (2005) · JAMA · doi:10.1001/jama.294.3.326 · Cited by 744
Cholesterol and Coronary Heart Disease: Predicting Risks by Levels and Ratios
Kinosian, B., Glick, H., & Garland, G. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-9-199411010-00002 · Cited by 519
Costa, J., Borges, M., David, C., & Carneiro, A. V. (2006) · BMJ · doi:10.1136/bmj.38793.468449.ae · Cited by 340
Okamura, T., Kokubo, Y., Watanabe, M., Higashiyama, A., Miyamoto, Y., Yoshimasa, Y., & Okayama, A. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.07.020 · Cited by 123
Cited by
Wanner, C., the Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members, & Tonelli, M. (2014) · Kidney International · doi:10.1038/ki.2014.31 · Cited by 649
Lipid management in patients with chronic kidney disease
Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P., Heine, G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., Valdivielso, J. M., Malyszko, J., et al. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0072-9 · Cited by 273
Kones, R. (2011) · Drug Design, Development and Therapy · doi:10.2147/dddt.s14934 · Cited by 259
Tonelli, M., Wanner, C., & for the Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members* (2014) · Annals of Internal Medicine · doi:10.7326/m13-2453 · Cited by 226
“Given the lack of data to support this approach in populations with and without CKD (32), the substantial within-person variability in LDL cholesterol measurements (33) and the potential for medication-related toxicity (including direct effects on muscle and liver, and indirect effects mediated through drug interactio…”
BackgroundSurveillance for ocular hypertension: an evidence synthesis and economic evaluation.
Burr, J., Botello-Pinzon, P., Takwoingi, Y., Hernández, R., Vazquez-Montes, M., Elders, A., Asaoka, R., Banister, K., van der Schoot, J., Fraser, C., et al. (2012) · Health Technology Assessment · doi:10.3310/hta16290 · Cited by 180
Self-citation
Metadata
- Authors
- Takahashi, O., Glasziou, P. P., Perera, R., Shimbo, T., Suwa, J., Hiramatsu, S., & Fukui, T.
- Venue
- Heart
- Publisher
- BMJ
- Published
- 2009-06-14
- Volume
- 96
- Issue
- 6
- Pages
- 448-452
- ISSN
- 1355-6037 (ISSN-L)
- 1468-201X
- OpenAlex
- W2152527066
- Cited by
- 46
- References
- 5
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipid re-screening: what is the best measure and interval? https://app.cochat.ai/papers/10.1136/hrt.2009.172619
- The paper
- Takahashi, O., Glasziou, P. P., Perera, R., Shimbo, T., Suwa, J., Hiramatsu, S., & Fukui, T. (2010). Lipid re-screening: what is the best measure and interval? Heart. https://doi.org/10.1136/hrt.2009.172619
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.